Pretax income is the income that a company earns before paying income taxes. Verona Pharma's pretax income for the
three
months ended in Sep. 2024 was $-42.71 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-151.76 Mil.
Verona Pharma's pretax margin was -759.46%.
During the past 13 years, Verona Pharma's highest Pretax Margin was -138.97%. The lowest was -14944.98%. And the median was -7541.98%.
Verona Pharma Pre-Tax Income Historical Data
The historical data trend for Verona Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Verona Pharma's Pre-Tax Income
For the Biotechnology subindustry, Verona Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verona Pharma's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verona Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Verona Pharma's Pre-Tax Income falls into.
Verona Pharma Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Verona Pharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-151.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verona Pharma (NAS:VRNA) Pre-Tax Income Explanation
Verona Pharma's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 13 years, Verona Pharma's highest Pretax Margin was -138.97%. The lowest was -14944.98%. And the median was -7541.98%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verona Pharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Verona Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRNA has been successfully added to your 